Caffeine in Your Blood Could Affect Body Fat And Diabetes Risk, Study Reveals
Those are the findings of a 2023 study that used genetic markers to establish a more definitive link between caffeine levels, BMI, and type 2 diabetes risk.
The research team, from the Karolinska Institute in Sweden, the University of Bristol in the UK, and Imperial College London in the UK, said calorie-free caffeinated drinks could be explored as a potential means of helping reduce body fat levels.
"Genetically predicted higher plasma caffeine concentrations were associated with lower BMI and whole body fat mass," the researchers wrote in their paper, published in March 2023.
"Furthermore, genetically predicted higher plasma caffeine concentrations were associated with a lower risk of type 2 diabetes. Approximately half of the effect of caffeine on type 2 diabetes liability was estimated to be mediated through BMI reduction."
The study involved data from just under 10,000 people collected from existing genetic databases, focusing on variations in or near specific genes known to be associated with the speed at which caffeine is broken down.
In general, those with variations affecting the genes – namely CYP1A2 and a gene that regulates it, called AHR – tend to break caffeine down more slowly, allowing it to remain in the blood longer. Yet they also tend to drink less caffeine in general.
An approach called Mendelian randomization was used to determine likely causal relationships between the presence of the variations, illnesses like diabetes, body mass, and lifestyle factors.
While there was a significant link between caffeine levels, BMI, and type 2 diabetes risk, no relationship emerged between the amount of caffeine in the blood and cardiovascular diseases including atrial fibrillation, heart failure, and stroke.
Previous studies have linked a moderate and relative increase in caffeine consumption to better heart health and a lower BMI, and this research adds more detail to what we already know about the effects that coffee has on the body.
It's important to also keep in mind the impacts of caffeine on the body aren't all positive, which means care must be taken when weighing up the benefits of drinking it – but this latest study is an important step in assessing how much caffeine is ideal.
"Small, short term trials have shown that caffeine intake results in weight and fat mass reduction, but the long term effects of caffeine intake is unknown," the researchers explained.
"Considering the extensive intake of caffeine worldwide, even its small metabolic effects could have important health implications."
The team thinks the association shown here could be down to the way caffeine increases thermogenesis (heat production) and fat oxidation (turning fat into energy) in the body, which both play an important role in overall metabolism.
While this study involved a large sample, Mendelian randomization isn't infallible, and it's still possible that other factors are at play that weren't accounted for. More research will be needed to confirm cause and effect.
"Randomized controlled trials are warranted to assess whether non-caloric caffeine containing beverages might play a role in reducing the risk of obesity and type 2 diabetes," said University of Bristol genetic epidemiologist Benjamin Woolf.
The research was published in BMJ Medicine.
An earlier version of this article was published in March 2023.
Leading Cause of Death in US Claims A Life Every 34 Seconds
Surprising Link Between Menthol And Alzheimer's Discovered in Mice
AI Can Predict Breast Cancer Risk Years Before Diagnosis, Study Finds
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
Chemotherapy Linked to Brain Atrophy in Breast
Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new findings from a pilot study suggested. Memory problems in patients with cancer may not stem solely from stress or anxiety related to their diagnosis but could reflect underlying changes in brain structure, study investigator Paul Edison, PhD, MPhil, professor of neuroscience and clinical professor of neurology at Imperial College London, London, England, told Medscape Medical News . While the findings suggest that chemotherapy may contribute to neuronal damage, the researchers noted that many aspects of the relationship between treatment and brain changes remain unclear. Edison highlighted three key areas that require further investigation — uncovering the mechanisms driving brain atrophy, determining the proportion of patients affected, and identifying effective prevention strategies. Another investigator on the study, Laura Kenny, MD, PhD, associate professor and consultant medical oncologist at Imperial College London, noted that the issue has received limited attention to date but expressed hope that the findings will raise awareness and encourage further research, given its clinical importance. The findings were presented on July 29 at the Alzheimer's Association International Conference (AAIC) 2025. Investigating Cognitive Impact Advances in chemotherapeutic agents have improved survival rates in patients with cancer. However, challenges persist regarding the long-term impact of these drugs. Chemotherapy-associated cognitive impairment, often referred to as 'brain fog' or 'chemobrain,' affects approximately one third of patients with breast cancer following treatment. While cognitive decline resolves within 12 months for some patients, others experience persistent effects that may elevate the risk for neurodegenerative conditions, Edison explained. To evaluate the impact of chemotherapy on the brain, investigators studied 328 women with nonmetastatic breast cancer who had undergone chemotherapy within the past 12 months. Patients received either anthracycline — a drug derived from the Streptomyces peucetius bacterium — or taxanes such as docetaxel and paclitaxel, both commonly used in breast cancer treatment, or a combination of these agents. In addition, some patients may also have had hormone therapy at some point during treatment, said Kenny. Participants completed neurocognitive prescreening tests every 3 months using a specialized artificial intelligence-driven platform, allowing them to take detailed memory assessments online from home. Among those prescreened, 18 individuals with lower neurocognitive scores (mean age, approximately 55 years) and 19 cognitively normal control individuals without breast cancer (mean age, approximately 67 years) underwent comprehensive, in-person, neurocognitive evaluations and MRI scans. Researchers analyzed the scans using region of interest (ROI) and voxel-based morphometry (VBM), which uses sophisticated computer software, to assess grey matter volumes and surface areas. The ROI analysis revealed significant reductions in gray matter volume (measured in mm3) and surface area (measured in mm2) among patients experiencing chemobrain, particularly affecting the isthmus cingulate and pars opercularis, with changes extending into the orbitofrontal and temporal regions. Significant Atrophy The VBM analysis confirmed significant atrophy in the frontal, parietal, and cingulate regions of patients with chemobrain compared with control individuals ( P < .05). Edison noted that this pattern overlaps with brain changes typically observed in Alzheimer's disease and vascular cognitive impairment. For both analyses, 'we demonstrated there is some amount of shrinkage in the brain among patients with chemobrain.' he said. 'The fact that controls are older means the results are even more significant as there's more brain atrophy as people age.' Some of the affected brain regions may be linked to impaired memory, a hallmark of Alzheimer's disease, but Edison cautioned that given the small sample size this finding should be interpreted with caution. While the analysis demonstrated overall lower brain volumes in patients with 'chemobrain' compared with controls, Edison emphasized that this finding reflects a single time point and does not indicate brain shrinkage over time. Other events, including stroke — can also cause brain changes. Edison highlighted the importance of determining the significance of these brain changes, how they affect patients and whether they can be prevented. In-person neurocognitive testing revealed significantly reduced semantic and verbal fluency, as well as lower Mini-Mental State Examination scores in patients with chemobrain. Edison noted that these results support the MRI findings. The team plans to follow patients to track brain changes and memory recovery, Kenny said. While patients with breast cancer are a common focus, the researchers intend to expand the study to other cancers in both men and women, said Kenny. Anecdotally, many patients report memory problems during chemotherapy, she added. Based on discussions with her oncology colleagues, Kenny noted that many patients anecdotally report experiencing memory problems during chemotherapy. More Research Needed Commenting for Medscape Medical News , Rebecca M. Edelmayer, PhD, vice president, Scientific Engagement, at the Alzheimer's Association, said the research may help shed light on why women are more likely to develop dementia than men. For years now, experts have been trying to figure out what puts women at higher risk for AD and other dementias, said Edelmayer. 'We still don't understand whether this involves biologically driven risk factors or socially driven risk factors.' Research linking treatments for other health conditions to increased memory problems may offer some clues, she noted, suggesting a potential avenue for further investigation into the intersection of chemotherapy and neurodegenerative diseases such as Alzheimer's. However, Edelmayer emphasized that this line of research is still in its infancy. Much more work is needed to determine whether there is a direct cause-and-effect relationship with specific chemotherapy drugs, and whether some patients may already be predisposed or at higher risk for cognitive decline, she said. Also commenting for Medscape Medical News , Eric Brown, MD, associate scientist and associate chief of geriatric psychiatry at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada, raised concerns about the study's design. One issue, he noted, is that the researchers did not image all patients who received chemotherapy but instead selected those with the most significant cognitive impairment. As a result, the findings may not have reflected outcomes in the average post-chemotherapy patients but rather represent the most severely affected subgroup. Brown also pointed out that the study did not clarify whether this subgroup had comorbid conditions. It's possible, he said, that some individuals may have had Alzheimer's disease or other forms of dementia unrelated to chemotherapy. He agreed that tracking longitudinal changes in both cognitive scores and neuroimaging — comparing patients who receive chemotherapy with those who do not — would be a valuable next step.
Fox News
21-07-2025
- Fox News
Trained dogs can smell Parkinson's disease before symptoms show up, study finds
Man's best friend could provide more than just companionship. In a new study from the University of Bristol, dogs were found to detect Parkinson's disease well before symptoms appear. Previous research has shown that people with Parkinson's have increased amounts of sebum — an oily, waxy substance with a distinctively musky odor — on the skin. In the new study, two dogs that had been trained on more than 200 odor samples were presented with skin swabs from 130 people with Parkinson's and 175 people without the disease, according to a press release. The dogs — a golden retriever named Bumper and a black labrador named Peanut — were rewarded for positively identifying Parkinson's samples and for ignoring negative ones. The dogs showed sensitivity of up to 80% — which means they identified people who had the disease 80% of the time. They achieved specificity of up to 98%, which is how good they were at ruling out people who did not have Parkinson's. "The dogs … showed there is an olfactory signature distinct to patients with the disease." The University of Bristol collaborated with Medical Detection Dogs and the University of Manchester on the study, which was published in The Journal of Parkinson's Disease on July 15. While there is no early screening available for Parkinson's, some early warning signs can appear years or even decades before diagnosis, according to experts. "Identifying diagnostic biomarkers of PD, particularly those that may predict development or help diagnose disease earlier, is the subject of much ongoing research," said lead study author Nicola Rooney, associate professor at Bristol Veterinary School at the University of Bristol, in the release. "The dogs in this study achieved high sensitivity and specificity and showed there is an olfactory signature distinct to patients with the disease," she went on. "Sensitivity levels of 70% and 80% are well above chance, and I believe that dogs could help us to develop a quick, non-invasive and cost-effective method to identify patients with Parkinson's disease." Claire Guest, chief scientific officer at Medical Detection Dogs in the U.K., reiterated that the study confirmed dogs can "very accurately" detect disease. "Timely diagnosis is key, as subsequent treatment could slow down the progression of the disease and reduce the intensity of symptoms," she said in the release. Perdita Barran, professor of mass spectrometry at The University of Manchester, said the study "adds to the growing body of evidence showing that simple, non-invasive skin swabs can be used to diagnose Parkinson's disease, offering a faster and more accessible method for early detection." For more Health articles, visit Looking ahead, the team plans to conduct longer-term studies to assess dogs' capacity to detect Parkinson's before diagnosis. The Michael J. Fox Foundation and Parkinson's UK provided funding for this study.
Yahoo
18-07-2025
- Yahoo
Universities awarded funding to help recruit ‘world's top researchers' to UK
A group of leading universities and research organisations has been selected to deliver a £54 million Government fund to recruit world-leading researchers to the UK. The Global Talent Fund, administered by UK Research and Innovation (UKRI), aims to attract up to 80 researchers in high-priority sectors such as life sciences and digital technologies. Twelve universities and research institutions across the UK have secured an equal share of the fund to help bring some of the world's foremost researchers and their teams to the UK. The institutions selected are: University of Bath; Queen's University Belfast; University of Birmingham; University of Cambridge; Cardiff University; Imperial College London; University of Oxford; University of Southampton; University of Strathclyde; University of Warwick; John Innes Centre and MRC Laboratory of Molecular Biology. The five-year Government fund, which starts in 2025/26, will cover all eligible costs with no requirement for match funding from research organisations. Visa and relocation costs for researchers and their family members will be covered by the fund. Science minister Lord Vallance said: 'Genius is not bound by geography. But the UK is one of the few places blessed with the infrastructure, skills base, world-class institutions and international ties needed to incubate brilliant ideas, and turn them into new medicines that save lives, new products that make our lives easier, and even entirely new jobs and industries. 'Bringing these innovations to life, here in Britain, will be critical to delivering this Government's Plan For Change. 'My message to the bold and the brave who are advancing new ideas, wherever they are, is: our doors are open to you. 'We want to work with you, support you, and give you a home where you can make your ideas a reality we all benefit from.' Chancellor Rachel Reeves said: 'The UK is home to some of the world's best universities which are vital for attracting international top talent. 'Supported by our new Global Talent Taskforce, the Global Talent Fund will cement our position as a leading choice for the world's top researchers to make their home here, supercharging growth and delivering on our Plan For Change.'
